

Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum

Borja Quiroga ¹, María José Soler,^{2,3} Alberto Ortiz ^{3,4}, Esther Orero,⁵ Sandra Tejedor,⁵ Carlos Jesús Jarava Mantecón,⁶ Virginia Olinda Gómez Pérez,⁶ Antonio José Marín Franco,⁷ Christian Alfaro Sánchez,⁷ Marta Puerta Carretero,⁸ María Teresa Jaldo Rodríguez,⁸ Manuel Antonio Carnerero Di Riso,⁹ Shaira Martínez,⁹ Carmen Calderón González,¹⁰ Michal Cervienka,¹⁰ Nicolás Macías Carmona,¹¹ David Arroyo,¹¹ Katia M. Pérez del Valle,¹² Gabriel de Arriba,¹² Auxiliadora Mazuecos,¹³ Juan Manuel Cazorla,¹³ Mónica Pereira,⁴ Emilio González Parra,⁴ María Gabriela Sánchez Márquez,¹⁴ Carolina Lancho Novillo,¹⁴ Carmen Toyos Ruiz,¹⁵ María Cinta Aguilar Cervera,¹⁵ Patricia Muñoz Ramos,¹ Ana Sánchez Horrillo,¹ Isabel Jimeno Martín,¹⁶ Néstor Toapanta ², Secundino Cigarrán Guldres ¹⁷, Montserrat Folgueiras López,¹⁸ Rosalía Valero San Cecilio,¹⁹ Blanca Villacorta Linaza,²⁰ Ignacio Minguela Pesquera,²¹ Raquel Santana Estupiñán,²² Rocío Zamora,²³ Sagrario Soriano,²⁴ Eduardo Muñoz de Bustillo,²⁵ María Soledad Pizarro Sánchez,²⁶ Ana Isabel Martínez Puerto ²⁷, Alejandra Yugueros,²⁸ Laura Muñiz Pacios,²⁹ Alba Leyva,³⁰ José Rojas,³⁰ Ron T. Gansevoort,³¹ and Patricia de Sequera,^{3,8} on behalf of SENCOVAC collaborative network*

CJASN 17: ●●●●●, 2022. doi: <https://doi.org/10.2215/CJN.01770222>

Information on the effect of a third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in advanced CKD is incomplete (1). We assessed the humoral response up to 6 months after receipt of two or three doses of the SARS-CoV-2 vaccine across the CKD spectrum. SENCOVAC is a prospective, multicentric study of four cohorts of patients with CKD: kidney transplant, hemodialysis (HD), peritoneal dialysis (PD), and nondialysis CKD (eGFR <30 ml/min per 1.73 m²) (2,3). Patients were vaccinated against SARS-CoV-2 during routine clinical care. Some patients received a third dose of an mRNA vaccine. This depended on the timing of vaccination drives by local health authorities. We assessed anti-Spike antibodies (CLIA, Covid-19 Spike Quantitative Virclia IgG Monotest; Vircell SL, Spain) kinetics at a prespecified 6-month time point after completing the original vaccination schedule (2,3). The study was approved by the ethics committee of Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD) (February 2021).

Antibody titers were assessed at 28 days in 1736 patients, 3 months in 1371 patients, and 6 months in 1008 patients. At 6 months, 175 (17%) were kidney transplant recipients, 64 (6%) were on PD, 698 (70%) were on HD, and 71 (7%) were patients with CKD. Patients had received two doses of BNT162b2 (Pfizer-BioNTech; 305, 30%) or mRNA-1273 (Moderna; 703, 70%). Additionally, 624 (65%) patients received a third dose (26% BNT162b2, 74% mRNA-1273): 118 (71%) kidney transplant recipients, 20 (37%) patients on PD, 451 (67%) patients on HD, and 35 (51%) patients with CKD. The third dose was given a median of 144 (111–170) days after the second dose (125 [85–156] days in kidney transplant recipients, 145 [125–183] days in patients on PD,

147 [115–174] days in patients on HD, and 148 [125–188] days in patients with CKD).

Six months after completing the initial vaccination schedule, anti-Spike titers were lower in kidney transplant recipients than in patients on HD ($P<0.001$) (Figure 1A). Similarly, among patients with negative baseline anti-Spike antibodies, kidney transplant recipients had lower anti-Spike antibodies titers at 6 months than patients on HD ($P<0.001$). Anti-Spike antibody titers were lower in patients on PD than in those on HD ($P=0.001$). At 6 months, patients who had received a third vaccine dose had higher anti-Spike antibody titers than those without the third dose ($P<0.001$) in all CKD cohorts. Among patients who did not receive a third dose, antibody titers decreased significantly from 3 to 6 months ($P<0.001$).

According to the manufacturer, a positive humoral response was defined as anti-Spike IgG titers >36 U/ml. A positive response at 6 months among those receiving versus not receiving a third dose, by CKD subgroup, was as follows: 94 of 118 (80%) versus 25 of 47 (53%; $P=0.002$) kidney transplant recipients, respectively; 20 of 20 (100%) versus 24 of 34 (71%; $P=0.01$) patients on PD, respectively; 432 of 451 (96%) versus 138 of 217 (64%; $P<0.001$) patients on HD, respectively; and 34 of 35 (97%) versus 24 of 33 (73%; $P=0.02$) patients with CKD, respectively (Figure 1B). These responses were higher than in patients without a third dose ($P<0.001$). Among patients without humoral response at 3 months, 72 (69%) seroconverted after the third dose. The percentage of seroconverted patients was numerically higher with a third dose of mRNA-1273 (58%) than of BNT162b2 (38%; $P=0.07$). Among the CKD cohorts, 36 of 58 (62%) kidney transplant recipients, 34 of 45 (76%) patients

Due to the number of contributing authors, the affiliations are listed at the end of this article.

Correspondence:
Dr. María José Soler,
Nephrology
Department, Vall
d'Hebron Hospital,
Passeig Vall d'Hebron
119-129, Barcelona,
Spain 08035, or
Dr. Alberto Ortiz,
Nephrology
Department, Fundación
Jiménez Díaz and
School of
Medicine, Instituto de
Investigación Sanitaria-
Fundación Jiménez
Díaz, University
Autónoma of
Madrid, Fundación
Renal Íñigo Álvarez de
Toledo and Red de
Investigación Renal,
Madrid, Spain. Email:
mjsoler01@gmail.com
or aortiz@fjd.es




Figure 1. | Anti-Spike antibodies during follow-up in CKD cohorts. (A) Anti-Spike antibodies titers during follow-up in different CKD cohorts. Data show anti-Spike antibodies titers of all patients irrespective of their baseline anti-Spike antibody titers. (B) Presence of anti-Spike antibodies during follow-up in the different CKD cohorts. Data are expressed as the percentage of patients with the presence of anti-Spike antibodies (i.e., titer >36 IU/ml). The table shows the sample size of each CKD group across each time point. Only significant *P* values are shown. HD, hemodialysis; PD, peritoneal dialysis.

on HD, and two of two (100%) patients with CKD seroconverted after the third dose.

In an adjusted multivariable model using logistic regression, a positive humoral response at 6 months was associated with initial mRNA-1273 vaccine (hazard ratio [HR], 1.78; 95% confidence intervals [95% CI], 1.11 to 2.88; $P=0.02$), a positive humoral response at 3 months (HR, 26.2; $P<0.001$), having received a third dose (HR, 22.9; 95% CI, 8.06 to 65.2; $P<0.001$), and not being a kidney transplant recipient (HR for kidney transplant recipients, 0.26; 95% CI, 0.09 to 0.73; $P=0.01$). In patients with 3-month negative humoral response, a third dose (HR, 27.8; 95% CI, 5.12 to 150.0; $P<0.001$) and not being a kidney transplant recipient (HR for kidney transplant recipients, 0.11; 95% CI, 0.02 to 0.74; $P=0.02$) were associated with a humoral response at 6 months in a model adjusted for age, type of initial and subsequent mRNA vaccine, and baseline anti-Spike antibodies.

The limitations are a small sample size, especially for some of the CKD subgroups that did not receive a third dose; that the timing of the third dose (between the third and sixth months) was variable and not accounted for in describing these results; and that the study did not assess cellular immunity or clinical efficacy (4).

In conclusion, the pragmatic analysis of the SENCovac study reveals that anti-Spike antibodies continue to decrease from 3 to 6 months after vaccination in patients with CKD. A third dose of SARS-CoV-2 vaccine induces seroconversion in a high percentage of antibody-negative patients with CKD after two doses, although responses were poorer in kidney transplant recipients.

Disclosures

C. Alfaro Sánchez and E. Orero report employment with Diaverum. D. Arroyo reports consultancy agreements with Vifor Pharma; honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Otsuka, UCB Pharma, and Vifor Pharma; and honoraria for conferences, consulting fees, and advisory boards from Amgen, AstraZeneca, Baxter, Boehringer Ingelheim, Eli Lilly, Esteve, Otsuka, Sanofi-Genzyme, and Vifor-Pharma. J.M. Cazorla has received honoraria for conferences from Astellas and AstraZeneca. S. Cigarrán Guldries reports consultancy agreements with Abbott, Boehringer, Nipro, Novartis, and Novo Nordisk; research funding from Abbott, AbbVie, Chiesi, Fresenius Medical Care, Maltrom, MSD, Nipro, and Shire; honoraria from Abbott, AbbVie, Chiesi, Fresenius Medical Care, Maltrom, MSD, Nipro, and Shire; honoraria for conferences, consulting fees, and advisory boards from Amgen, Astellas, AstraZeneca, Boehringer, Chemo-Centrix, Chiesi, Novartis, Novo Nordisk, Otsuka, Rovi, Sanofi-Genzyme, and Vifor-Pharma; serving in an advisory or leadership role for AbbVie, Maltrom, MSD, and Shire; serving on the editorial board of *Journal of Diabetes Research*; speakers bureau for AbbVie, AstraZeneca, MSD, Nipro, and Shire; and other interests or relationships with Sociedad Española de Nefrología. P. de Sequera reports consultancy agreements with Alexion, Astellas, AstraZeneca, Baxter, Nipro, and Vifor Pharma; research funding from Baxter; honoraria from Amgen, AstraZeneca, Baxter, Fresenius, Nipro, and Vifor Pharma; serving in an advisory or leadership role for Astellas, AstraZeneca, Baxter, and Vifor Pharma; and speakers bureau for Alexion, Amgen, AstraZeneca, Baxter, Braun, Fresenius, Nipro, and Vifor Pharma. P. de Sequera reports honoraria for conferences, consulting fees, and advisory boards from Amgen, Astellas,

AstraZeneca, Baxter, Braun, Fresenius, Nipro, and Vifor-Pharma. She is the present president of the Spanish Society of Nephrology. R.T. Gansevoort reports consultancy agreements with AstraZeneca, Bayer, Galapagos, Otsuka Pharmaceutical, and Sanofi-Genzyme; research funding from AstraZeneca, Bayer, Galapagos, Otsuka Pharmaceuticals, and Sanofi-Genzyme; honoraria from Bayer, Galapagos, Mironid, Otsuka Pharmaceuticals, and Sanofi-Genzyme; and serving in an advisory or leadership role for *American Journal of Kidney Diseases*, *CJASN*, *Journal of Nephrology*, *Kidney360*, *Nephrology Dialysis Transplantation*, and *Nephron Clinical Practice*. C.C. González reports honoraria for conferences, consulting fees, and advisory boards from AstraZeneca and Fresenius and speakers bureau for AstraZeneca. C.J.J. Mantecón reports employment with Diaverum and honoraria for one conference from Vifor-Pharma. A.J. Marin Franco reports employment with and honoraria from Diaverum Servicios Renales SL. A. Mazuecos has received honoraria for conferences, consulting fees, and advisory boards from Astellas, Chiesi, GSK, Novartis, and Sanofi-Genzyme. She is a member of the Board of the Spanish Society of Nephrology and the Spanish Society of Transplantation. A. Ortiz is the director of the Catedra Mundipharma Universidad Autónoma de Madrid (UAM) of diabetic kidney disease and the Catedra AstraZeneca UAM of CKD and electrolytes; reports consultancy agreements with Genzyme, Retrophin, and Sanofi; reports research funding from AstraZeneca, Mundipharma, and Sanofi Genzyme; reports honoraria from Advicciene, Alexion, Amgen, Amicus, Astellas, AstraZeneca, Bayer, Chiesi, Fresenius Medical Care, Idorsia, Kyowa Kirin, Menarini, Otsuka, Sanofi-Genzyme, and Vifor Fresenius Medical Care Renal Pharma; reports serving in an advisory or leadership role for the Dutch Kidney Foundation Scientific Advisory Board, European Renal Association (ERA) and Sociedad Madrileña de Nefrología (SOMANE) councils, and the board of directors of Instituto de Investigación Sanitaria (IIS)-Fundacion Jimenez Diaz UAM; reports serving as a Spanish Society of Nephrology member and as *Clinical Kidney Journal* Editor-in-Chief; reports serving on the editorial boards of *JASN*, *Journal of Nephrology*, and *Peritoneal Dialysis International*; and reports speaker engagements for Advicciene, Alexion, Amgen, Amicus, Astellas, AstraZeneca, Bayer, Chiesi, Fresenius Medical Care, Idorsia, Kyowa Kirin, Menarini, Otsuka, Sanofi-Genzyme, and Vifor Fresenius Medical Care Renal Pharma. M.S. Pizarro Sánchez reports honoraria from AstraZeneca. B. Quiroga reports consultancy agreements with Amgen, Astellas, AstraZeneca, Bial, Esteve, Ferrer, Laboratorios Bial, Novartis, Otsuka, Sandoz, Sanofi-Genzyme, and Vifor-Pharma; honoraria from Amgen, Astellas, AstraZeneca, Bial, Esteve, Ferrer, Laboratorios Bial, Novartis, Otsuka, Sandoz, Sanofi-Genzyme, and Vifor-Pharma; serving in an advisory or leadership role for Amgen, Astellas, AstraZeneca, Bial, Esteve, Ferrer, Novartis, Laboratorios Bial, Otsuka, Sandoz, Sanofi-Genzyme, and Vifor-Pharma; and other interests or relationships as the secretary of the Spanish Society of Nephrology. J. Rojas report employment with Viracell SL. M.J. Soler reports consultancy agreements with AstraZeneca, Bayer, Boehringer, Esteve, ICU Medical, Jansen, Mundipharma, Novo Nordisk, and Traveere Therapeutics; research funding from Abbvie and Boehringer; honoraria from AstraZeneca, Bayer, Boehringer, Esteve, FMC, ICU Medical, Ingelheim Lilly, Jansen, Mundipharma, Novo Nordisk, Otsuka, Traveere, and Vifor; patents or royalties for U691ES00; serving in an advisory or leadership role on the board of American Society of Nephrology news, for *Ex BMC Nephrology*, for CKJ, as elected Editor-in-Chief (EIC) of *Clinical Kidney Journal* (CKJ), as Ex ERA-EDTA council member, as Ex-Scientific Advisory Board (SAB) the European

Renal Association and the European Dialysis and Transplant Association (ERA-EDTA), for Kidney and Blood Pressure Research, and as a council member of the Spanish Society of Nephrology; speakers bureau for AstraZeneca, Bayer, Boehringer, Esteve, FMC, Jansen, Mundipharma, Novo Nordisk, and Vifor; and other interests or relationships with Sociedad Catalana de Nefrología (member) and Sociedad Española de Nefrología. S. Soriano reports honoraria for conferences and advisory boards from Astellas, Baxter, and Vifor-Pharma. S. Tejedor reports employment with Diaverum Gamapal SL. C. Toyos Ruiz reports employment with Sociedad Española de Nefrología. All remaining authors have nothing to disclose.

Funding

This project has been supported by Diaverum, Fresenius Medical Care, Fundación Renal Íñigo Álvarez de Toledo, Vifor Pharma, and Vircell.

Acknowledgments

We thank all of the involved centers and health care workers, especially the nurse team, for their work in this project. In addition, we thank the Sociedad Española de Enfermería Nefrológica, Organización Nacional de Trasplantes, and Sociedad Española de Trasplante for support.

Author Contributions

P. de Sequera, R.T. Gansevoort, A. Ortiz, B. Quiroga, and M.J. Soler conceptualized the study; C.J.J. Mantecón, A.J. Marín Franco, S. Martínez, E. Orero, and S. Tejedor were responsible for data curation; M.C. Aguilar Cervera, C. Alfaro Sánchez, D. Arroyo, M.A. Carnerero Di Riso, J.M. Cazorla, M. Cervienka, S. Cigarrán Guldri, G. de Arriba, M. Folgueiras López, V.O. Gómez Pérez, C.C. González, E. González Parra, M.T. Jaldo Rodríguez, I. Jimeno Martín, C. Llancho Novillo, N. Macías Carmona, C.J.J. Mantecón, A.J. Marín Franco, A.I. Martínez Puerto, A. Mazuecos, I. Minguela Pesquera, L. Muñoz Pacios, E. Muñoz de Bustillo, P. Muñoz Ramos, E. Orero, A. Ortiz, M. Pereira, K.M. Pérez del Valle, M.S. Pizarro Sánchez, B. Quiroga, A. Sánchez Horrillo, M.G. Sánchez Márquez, R. Santana Estupiñán, M.J. Soler, S. Soriano, S. Tejedor, N. Toapanta, C. Toyos Ruiz, R. Valero San Cecilio, B. Villacorta Linaza, and A. Yugueros were responsible for investigation; M. Puerta Carretero, B. Quiroga, M.J. Soler, and R. Zamora were responsible for formal analysis; P. de Sequera, A. Leyva, B. Quiroga, J. Rojas, and M.J. Soler were responsible for methodology; P. de Sequera, A. Ortiz, and J. Rojas were responsible for project administration; P. de Sequera and A. Leyva were responsible for resources; A. Leyva and J. Rojas were responsible for software; M.C. Aguilar Cervera, C. Alfaro Sánchez, D. Arroyo, J.M. Cazorla, M. Cervienka, S. Cigarrán Guldri, G. de Arriba, P. de Sequera, M. Folgueiras López, V.O. Gómez Pérez, C.C. González, E. González Parra, M.T. Jaldo Rodríguez, I. Jimeno Martín, C. Llancho Novillo, A. Leyva, N. Macías Carmona, C.J.J. Mantecón, A.J. Marín Franco, S. Martínez, A.I. Martínez Puerto, A. Mazuecos, I. Minguela Pesquera, L. Muñoz Pacios, E. Muñoz de Bustillo, M. Pereira, K.M. Pérez del Valle, M.S. Pizarro Sánchez, M. Puerta Carretero, A. Sánchez Horrillo, M.G. Sánchez Márquez, R. Santana Estupiñán, S. Soriano, N. Toapanta, C. Toyos Ruiz, R. Valero San Cecilio, B. Villacorta Linaza, A. Yugueros, and R. Zamora were responsible for validation; R.T. Gansevoort was responsible for visualization; S. Martínez and J. Rojas were responsible for funding acquisition; M.A. Carnerero Di Riso, V.O. Gómez Pérez, P. Muñoz Ramos, A. Ortiz, and J. Rojas provided supervision; B. Quiroga

wrote the original draft; and P. de Sequera, E. Orero, A. Ortiz, B. Quiroga, M.J. Soler, and S. Tejedor reviewed and edited the manuscript.

Data Sharing Statement

The data underlying this article will be shared on reasonable request to the corresponding authors.

Supplemental Material

This article contains the following supplemental material online at <http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.01770222/-/DCSupplemental>.

Supplemental Summary 1. A list of the SENCovAC collaborative network nonauthor contributors.

References

- Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, Eder M, Regele F, Doberer K, Spechtl P, Aschauer C, Koblichke M, Paschen C, Eskandary F, Hu K, Öhler B, Bhandal A, Kleibenböck S, Jagoditsch RI, Reiskopf B, Heger F, Bond G, Böhmig GA, Strassl R, Weseslindtner L, Indra A, Aberle JH, Binder M, Oberbauer R: Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: A randomized clinical trial. *JAMA Intern Med* 182: 165–171, 2022
- Quiroga B, Soler MJ, Ortiz A, Vaquera SM, Mantecón CJJ, Useche G, Márquez MGS, Carnerero M, Rodríguez MTJ, Ramos PM, Millán JCRS, Toapanta N, Gracia-Iguacel C, Cervera MCA, Lara NB, Leyva A, Rojas J, Gansevoort RT, de Sequera P: Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: The SENCovAC study [published online ahead of print November 12, 2021]. *Nephrol Dial Transplant* 10.1093/ndt/gfab313
- Quiroga B, Soler MJ, Ortiz A, Bernat A, Díaz ABM, Mantecón CJJ, Pérez VOG, González CC, Cervienka M, Mazuecos A, Cazorla JM, Riso MCD, Martínez S, Díaz MO, Valverde RL, Márquez MGS, Novillo CL, Parra EG, Gracia-Iguacel C, De Tomas MTR, Cervera MCA, Giorgi M, Ramos PM, Carmona NM, Toapanta N, Guldri SC, Millán JCRS, Estupiñán RS, Crespo M, Linaza BV, Martín MJ, Jiménez LR, Soriano S, Ferri DG, Sánchez MSP, Yugueros A, Leyva A, Rojas J, Gansevoort RT, de Sequera P, Carretero MP, Tocora DG, Rodríguez MJ, Zanón TT, Suárez ER, Santolaya AJ, Calero RC, Cobo PA, Martín-Cleary C, Sánchez-Rodríguez J, Pereira M, Ramos-Verde A, Sánchez C, Giraldo YG, Horrillo AS, Suárez PR, Perpén AF, Ramos AF, Villanueva LS, Cortiñas A, Arias PAD, Cárdenas AC, de Santos A, Núñez A, Cuadrado GB, Repollet R, Moreso F, Azancot MA, Ramos N, Bestard O, Cidraque I, Bermejo S, Agraz I, Prat O, Medina C, Pardo E, Saiz A, Vila MAM, Granados NM, Cabo MJC, Alarcón WL, Alexandru S, Suarez LGP, Saico SP, Tapia MP, Hernández RS, García-Fernández N, Moreno PLM, González NA, Ortiz AS, Iñarrea MNB, López RO, Peregrí CM, Morales MLA, Cabello MDN, Ribera AMT, Valcarce EG, Vergara EG, García T, Narváez C, Orellana C, Ganga PLQ, Carrión FV, Herrera ALG, Chamoun B, Barbosa F, Faura A, Pachón DR, Castro NB, Cendrero RMR, Hidalgo-Barquero MVM, Gallego RH, Álvarez Á, Leo EV, León JLP, García MAM, Jiménez BG, Moya JDR, Espinosa DL, Herrador AJ, Zurita MN, Álvarez LD, Martínez ÁG, Arroyo SB, Fernández RR, Vargas MJS, Casero RC, Useche G, de Miguel CS, Palacios Á, Henningsmeyer B, Calve EO, Moya JL, Sato Y, Marín MS, Torres I, Conde PD, Alfaro G, Halauro O, Rifai FEL, Martínez AD, Ávila PJ, Franco AM, Sainz MS, Martín JMB, García LDR, Canga JLP, Ochoa PMV, Pacios LM, Machado LL, Morales AQ, Cavalotti IM, Zorita IN, López SO, González SO, Montañez CS, Rubio AB, Gilsanz GDP, Gonzalez MO, Villanueva RS, Oliva MOL, Varela JC, Enríquez AG, Casas CC, Alonso PO, Tabares LG, Barreiro JML, Solla LP, Gándara A, de la Garza WN, Fleming FF, Goyanes MGR, Feijoo CC, Plaza MMM, Juan CB, Cecilio RVS, Haces CP, Kislikova M, Rodrigo E, Contreras FJP, Lara NB, Llorente EMB, Díaz LS, Bustamante AMC, Ruiz JM, Rodríguez

EG, Perez VLM, Arevalo MC, Calvo JAH, Carratalá MRL, Rodríguez LMM, Salazar MS, Prieto BB, Pérez JMP, Rueda DA, Ferrero MLR, Martínez AV, Estébanez SA, Paraíso AG, Huarte E, Lanau M, Campos RA, Ubé JM, Pérez PS, Godoy IB, Aguilera ET, Alea RT, Saldaña MS DR, Salvetti ML, Valmajor MC, Sánchez MP, Barragán ML, Aunatell LR, Salgueira M, Aresté N, de Los Angeles Rodríguez M, Collantes R, Martínez AI, Moyano MJ, Vibora EJ, Gash SC, Martínez LR, Prieto BA, Toyos C, Río JM, Acosta AR, Zamacona AC, Ortega SB, Ruiz MIG, Rubio AH, Ledesma PG, Alvarez AG, de Briñas EPL, Cucchiari D, Monzo JB, Cabrera BE, Hernández APR, Rebollo MSG, Hernández JMR, Alonso JC, Más AM, Calvé M, Cardona MG, Balaguer VC, Pesquera JIM, Serrano AG, Simó PT, Mancilla HDR, Gómez MP, Gumpert JV, de la Fuente GA, Del Valle KP, de la Rosa EC, Santarelli DR, García AS, Martín-Caro AC, Santamaria IM, Umpierrez AM, Ruiz EH, Corbella AM, Perdomo KT, Martín YM, de la Pisa AMU, Monzon LS, Anachuri KA, García EH, Gomez VO, Amado FV, Borges PP, Vázquez RM, Beloso MD, Alonso FA, Felipe NP, Ameneiro AM, Mera MC, Casares BG, Larrondo SZ, Kareaga NM, Del Valle AISS, García ARM, Del

Toro Espinosa N, Perico PE, Oliva JMS, Manrique J, Castaño I, Purroi C, Gómez N, Mansilla C, Utzurum A: Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: The multicentric SENCOCVAC study [published online ahead of print January 11, 2022]. *Nephrol Dial Transplant* 10.1093/ndt/gfac007

4. Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, Chalencon E, Kalbacher E, Mathias V, Ovize A, Cart-Tanneur E, Bouz C, Pellegrina L, Morelon E, Juillard L, Fouque D, Couchoud C, Thauinat O: A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. *Kidney Int* 101: 390–402, 2022

*The list of nonauthor contributors is extensive and has been provided in Supplemental Summary 1.

Published online ahead of print. Publication date available at www.cjasn.org.

AFFILIATIONS

¹Instituto de Investigación Sanitaria-La Princesa, Nephrology Department, Hospital Universitario de la Princesa, Madrid, Spain

²Nephrology Department, Vall d'Hebrón University Hospital, Barcelona, Spain

³Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), RICORS2040 (Kidney Disease), Spain

⁴Nephrology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, School of Medicine, Universidad Autónoma de Madrid, Fundación Renal Iñigo Álvarez de Toledo-IRSIN, Red de Investigación Renal, Instituto de Investigación Carlos III, Madrid, Spain

⁵Dialysis Center, Diaverum, Valencia, Spain

⁶Dialysis Center, Diaverum, Andalucía, Spain

⁷Dialysis Center, Diaverum, Galicia, Spain

⁸Nephrology Department, Hospital Universitario Infanta Leonor–Universidad Complutense de Madrid, Spain

⁹Diaverum Murcia-Alicante, Spain

¹⁰Nephrology Department, Complejo Asistencial de Palencia, Spain

¹¹Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

¹²Nephrology Department, Hospital Universitario de Guadalajara, Spain

¹³Nephrology Department, Hospital Universitario Puerta del Mar, Cadiz, Spain

¹⁴Nephrology Department, Hospital Universitario Puerto Real, Cadiz, Spain

¹⁵Nephrology Department, Hospital Universitario de Donostia, Spain

¹⁶Nephrology Department, Hospital Universitario de Galdakao, Vizcaya, Spain

¹⁷Nephrology Department, Hospital Da Mariña, Lugo, Spain

¹⁸Nephrology Department, Hospital del Mar, Barcelona, Spain

¹⁹Nephrology Department, Hospital Marqués de Valdecilla, University of Cantabria, Instituto de Investigación Marqués de Valdecilla, Santander, Spain

²⁰Dialysis Unit, Centro Santa Isabel, Sevilla, Spain

²¹Nephrology Department, Hospital Universitario Basurto, Bilbao, Spain

²²Nephrology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

²³Nephrology Department, Hospital Universitario General de Villalba, Spain

²⁴Nephrology Department, Hospital Reina Sofía, Cordoba, Spain

²⁵Nephrology Department, Hospital General de Alicante, Spain

²⁶Nephrology Department, Hospital Rey Juan Carlos, Madrid, Spain

²⁷Nephrology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain

²⁸Nephrology Department, Hospital Lluís Alcanyis De Xàtiva, Valencia, Spain

²⁹Nephrology Department, Hospital Universitario Infanta Cristina, Madrid, Spain

³⁰Research and Development Department, Vircell Sociedad Limitada, Granada, Spain

³¹Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands